Dr. Kevin Scanlon's has a background that includes: academic medicine, senior management in the pharmaceutical industry, CEO of four start-up biotechnology companies and an angel investor. He is the Chairman Emeritus of Pasadena Angels Investment Group. Dr. Scanlon has worked with entrepreneurs, the investment community and international governments in Ireland, China and New Zealand to create an innovative culture around the intellectual property from their academic institutions. He is currently CEO of the stem cell technology company for skin care, Makucell. Makucell is one of four early stage biotechnology companies that he has helped spinout from academic institutions. As a Pharmaceutical Industry-Vice President at Berlex-Schering AG (Berlin, Germany), he was responsible for the company's international genomic and cancer research program in the US, Europe and Asia. Dr. Scanlon was a Leukemia Society Scholar, awarded the Paul Martini Medical Research Prize in Germany, a participant at 400th Anniversary of Uppsala University, Sweden, the President of the International Society of Cell and Gene Therapy, Co-Founder of the Nature journal "Cancer Gene Therapy", co-authored over 135 original scientific articles, edited nine medical books, a lead investigator on government grants and has seven issued US Patents.
Dr. Kevin Scanlon
@PPI_Ignite_DCU @DerekCStewart @PPI_NUIG @coileain @NicolaGaynor1 Critical to embrace PPI to understand how it can enrich our research and the way we communicate our findings @hrbireland @nicb_dcu @DcuBiotech @DCU_Cancer